Science Speaks
Plant Innovation Updates: Global Regulations for GMOs and Gene-Edited Products

Plant Innovation Updates: Global Regulations for GMOs and Gene-Edited Products

By Clement Dionglay

September 23, 2026

In the second half of 2026, the regulatory and technological landscape surrounding gene-edited plants continues to evolve at an unprecedented pace. Across global markets, governments are working to streamline oversight of modern breeding techniques while laboratories roll out novel gene-edited products—from high-GABA tomatoes to reduced-browning bananas and tear-free onions in Japan—breakthrough tools to solve long-standing bottlenecks in agricultural biotechnology.
This update tracks the important legal, technical, and commercial developments shaping the future of plant innovation worldwide.

Africa: Zimbabwe
In August 2026, Zimbabwe's National Biotechnology Authority (NBA) introduced new guidelines under Section 22 of the NBA Act, establishing a hybrid regulatory framework that accelerates the adoption of precision breeding. This model is consistent with the regional African approach pioneered by Nigeria and Kenya, using a 14-working-day pre-submission consultation process for Site-Directed Nuclease-1 (SDN-1) and SDN-2 edits. Crucially, it integrates the European Union's 20-nucleotide modification threshold for SDN-2 edits, exempting non-transgenic gene-edited crops from standard GMO regulations once foreign DNA segregation is confirmed. Building on earlier policy advancements in Burkina Faso and Ghana, Zimbabwe’s framework further expands a unified, science-based approach to new breeding technologies across Sub-Saharan Africa.

Americas: Panama
In July, Panama's National Biosafety Commission for Genetically Modified Organisms issued Resolution CNB 008-2026, establishing a science-based regulatory framework for gene-edited crops and organisms. Under these updated rules, products created using New Breeding Techniques (NBTs) such as CRISPR genome editing are classified and treated as conventional organisms, exempting them from traditional GMO regulations. To qualify for this conventional status, the edited organism must not contain any stable insertion of foreign recombinant genetic material that could not otherwise be produced through standard breeding or natural mutation, placing Panama alongside other Latin American nations updating their biosafety policies.

The new framework's administrative oversight relies on a Prior Consultation Request (ICP) system with two assessment paths. Developers in the early conceptual or laboratory stages can use an optional R&D ICP to receive non-binding regulatory guidance, while those seeking commercial market entry must submit a definitive ICP with full genetic, phenotypic, and procedural data for a binding evaluation. Applicants can seamlessly transition between these two stages without re-submitting previously verified data, with standard evaluations taking up to 80 business days or up to 120 days.

Asia: Pakistan and South Korea
Following draft approvals in May and June, Pakistan rolled out its newly approved National Agriculture Biotechnology Policy in July and August 2026. The policy establishes clear administrative mechanisms for precision breeding tools to accelerate climate resilience in crops and increase yield performance.

On July 8, 2026, South Korea's Ministry of Food and Drug Safety finalized revisions to the Labeling Standards for Genetically Modified Foods after the National Assembly approved amendments to the Food Sanitation Act. This shifts South Korea from a detection-based system to an ingredient-based standard, removing the exemption for highly processed foods in which modified DNA or proteins are refined away. Mandatory GMO labeling will roll out in phases, taking effect on December 31, 2026, for soy sauce products, and on December 31, 2027, for sugars, saccharides, and edible oils and fats. The reform also establishes a 3% unintentional contamination threshold supported by identity-preserved documentation or official certificates for non-GMO claims.

In contrast, legislative efforts to deregulate non-transgenic gene-edited organisms under the Act on Transboundary Movements of Living Modified Organisms (LMO Act) remain stalled. Despite draft bills and petitions from Korean scientists urging regulatory relief to exempt target-edited plants without foreign DNA from full LMO risk assessments, the proposed legislation has seen no substantial movement amid public debate and legislative inaction, leaving gene-edited crops under the same strict regulatory umbrella as traditional transgenic GMOs.

Europe: European Union and United Kingdom
After the European Council formally approved the EU’s New Genomic Techniques (NGT) framework (April 2026) and the European Parliament approved it (June 2026), the European Commission published a comprehensive implementation strategy outlining the operational roadmap. The framework officially entered into force on July 16, 2026 (20 days after its publication in the Official Journal of the EU), initiating a two-year transition period that will lead to full application across EU member states starting July 17, 2028.

The updated strategy streamlines oversight by establishing a risk-tiered framework and easing redundant safety testing:

Category 1 (NGT-1) Plants: Plants with minor, conventional-equivalent edits are exempt from standard GMO risk assessments, environmental reviews, and consumer-level labeling (though seed-level labeling remains mandatory).
Category 2 (NGT-2) Plants: Complex edits remain subject to traditional GMO regulation.

For stacked transgenic events, guidance from the European Food Safety Authority (EFSA) clarifies that certain stacked transgenic events will no longer require additional field trials or dietary exposure studies if their individual components have already received prior safety clearance.

Together, these updates significantly reduce administrative and testing burdens for low-risk NGT crops and pre-approved traits, bringing European agricultural biotech policy closer to North American standards.

Following the full operationalization of the Genetic Technology (Precision Breeding) Act 2023 and its 2025 Regulations, England has established a distinct, streamlined framework for Precision-Bred Organisms (PBOs)—plants with genetic edits that could occur naturally or via conventional breeding—moving them out of traditional GMO oversight through simplified DEFRA release/marketing notices and Food Standards Agency (FSA) food/feed authorizations.

Throughout 2026, DEFRA’s public Precision Breeding Register has actively processed notifications for research and commercial trials, enabling the first commercial farm trials in England. Notable crops that have officially received "precision bred" status under the Act include Rothamsted Research's gene-edited Camelina sativa (enriched with beneficial omega-3 fatty acids) and low-asparagine, low-acrylamide wheat designed to reduce food safety risks during baking.

Conclusion

The global landscape for agricultural biotechnology in late 2026 shows decisive worldwide momentum toward trait-based, risk-proportional regulation. From Sub-Saharan Africa to Latin America and the European Union, regulatory bodies are increasingly moving away from legacy, process-driven GMO frameworks toward streamlined pathways for non-transgenic, gene-edited crops. While jurisdictional divergences persist, such as South Korea's stricter processing labels and stalled LMO deregulation, the general trend favors harmonized science-based standards. Coupled with commercial deployments of consumer-beneficial and climate-resilient traits, these regulatory shifts pave the way for faster, lower-cost market entry for next-generation agricultural innovations.

For Further Reading: